Who We Are

SPIMACO: Advancing Pharmaceutical Excellence

SPIMACO is a leading pharmaceutical company specializing in the manufacturing, marketing, and distribution of high-quality medicines and healthcare products. With state-of-the-art production facilities in Saudi Arabia, Egypt, and Morocco, SPIMACO plays a key role in enhancing healthcare access across the Middle East and North Africa. Through its subsidiaries and strategic partnerships, the company continues to expand its reach in both regional and global markets.

About SPIMACO

SPIMACO is a distinguished Saudi joint-stock company with a fully paid-up capital of 1,200,000,000 SAR. Since its establishment in 1986, the company has emerged as a leader in the medical and pharmaceutical sector, excelling in the development, manufacturing, and distribution of pharmaceutical products and medical appliances.

Strategic Investments & Growth

Beyond its core business, SPIMACO has strategic investments in several joint-stock and limited liability companies, both within Saudi Arabia and globally. With a strong market presence, the company has built a solid foundation for sustainable growth, ensuring a robust platform for expanding into export markets.

World-Class Manufacturing

At the core of SPIMACO’s success is its Al-Qassim Pharmaceutical Plant, a state-of-the-art facility designed to meet the highest global quality standards. The company’s dedication to excellence has earned it numerous national quality awards and prestigious international certifications, reaffirming its reputation for superior manufacturing.

Market Leadership & Competitive Edge

SPIMACO has developed strong relationships with regulatory authorities and the medical community worldwide. By making significant investments in regulatory compliance, marketing, and international partnerships, the company continues to sharpen its competitive edge, consistently staying ahead in the industry.

Partnerships & Stock Market Presence

A key strength of SPIMACO lies in its dynamic collaborations with multinational corporations, built on flexibility and innovation. As a thriving joint-stock company, SPIMACO is a major player in the Saudi stock market, with its shares among the most actively traded, reinforcing its position as a leader in the pharmaceutical industry.

Our Pioneer Journey

Since its foundation, SPIMACO has been a true pioneer in the region’s pharmaceutical industry. From the establishment of the company to the production of our first Saudi made Biosimilar product, SPIMACO has always been a leader and an innovator.

1986

SPIMACO was launched

1990

First products manufactured

1990

Ministry of Health contract to produce first six products

1993

Exports to overseas markets

1993

SPIMACO listed on the Saudi Stock Market

1998

Drug development center in Qassim

2018

Operation of the automated warehouse

2018

Dammam Pharma SFDA Approval

2020

Oncology market products

2022

High Potent Plant opened

2023

Strategic plan launched

2024

Launching First Biosimilar Product

2025

Launch of the First Product from the High-Potency Pharmaceutical Plant

Subsidiaries, Associates and Joint Ventures

SPIMACO is a pharmaceutical sector leader and one of the region’s major companies. It has a large number of subsidiary firms that help to boost its presence and extend its activities in both local and international markets.

Geographical Presence

GCC

KSA

KUWAIT

OMAN

BAHRAIN

QATAR

UAE

LEVANT & YEMEN

IRAQ

JORDAN

LEBANON

YEMEN

AFRICA

ALGERIA

LIBYA

MOROCCO

EGYPT

SUDAN

SOUTH OF SUDAN

Manufacturing Capabilities

With a manufacturing capacity exceeding 2 billion units annually and 23 state-of-the-art automated production lines, we take pride in being one of the region’s leading pharmaceutical suppliers. Our facilities produce a diverse range of dosage forms, catering to a broad spectrum of healthcare needs